ArticleBMC cancer2020

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis.

A J N Raymakers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.